Equities research analysts forecast that Ascendis Pharma A/S (NASDAQ:ASND) will announce $2.58 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Ascendis Pharma A/S’s earnings, with the lowest sales estimate coming in at $2.42 million and the highest estimate coming in at $2.84 million. Ascendis Pharma A/S posted sales of $3.61 million during the same quarter last year, which indicates a negative year over year growth rate of 28.5%. The firm is expected to issue its next earnings results on Wednesday, August 26th.
On average, analysts expect that Ascendis Pharma A/S will report full year sales of $10.13 million for the current fiscal year, with estimates ranging from $2.42 million to $15.15 million. For the next fiscal year, analysts forecast that the firm will post sales of $80.44 million, with estimates ranging from $40.00 million to $130.43 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Ascendis Pharma A/S.
Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Tuesday, May 19th. The biotechnology company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.11. Ascendis Pharma A/S had a negative return on equity of 36.56% and a negative net margin of 2,231.94%. The firm had revenue of $2.45 million for the quarter, compared to analyst estimates of $2.66 million.
ASND stock traded down $2.91 on Monday, reaching $145.21. The company had a trading volume of 78,071 shares, compared to its average volume of 214,838. Ascendis Pharma A/S has a 1 year low of $90.06 and a 1 year high of $158.93. The company has a debt-to-equity ratio of 0.06, a quick ratio of 13.19 and a current ratio of 13.19. The company’s fifty day moving average is $143.34 and its 200 day moving average is $132.04. The company has a market cap of $7.04 billion, a P/E ratio of -27.22 and a beta of 0.97.
Institutional investors have recently made changes to their positions in the stock. Sowell Financial Services LLC purchased a new stake in Ascendis Pharma A/S during the 1st quarter worth $32,000. US Bancorp DE boosted its position in Ascendis Pharma A/S by 129.2% during the 4th quarter. US Bancorp DE now owns 385 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 217 shares during the period. Oppenheimer Asset Management Inc. purchased a new stake in Ascendis Pharma A/S during the 1st quarter worth $49,000. Tower Research Capital LLC TRC purchased a new stake in Ascendis Pharma A/S during the 1st quarter worth $52,000. Finally, Banque Cantonale Vaudoise purchased a new stake in Ascendis Pharma A/S during the 4th quarter worth $87,000. 99.96% of the stock is owned by hedge funds and other institutional investors.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Recommended Story: High-Yield Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.